{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"ONKORAS-101","nct_id":"NCT06343402","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=onkoras-101-nct06343402. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants enrolled in this cohort will receive BBO-8520 (different dose levels will be evaluated) once a day (QD) as monotherapy","label":"Cohort 1a - Dose Escalation/Dose Finding Monotherapy","type":"EXPERIMENTAL"},{"description":"Participants enrolled in this cohort will receive BBO-8520 (different dose levels will be evaluated) once a day (QD) in combination with pembrolizumab infusion (IV)","label":"Cohort 1b - Dose Escalation/Dose Finding Combination Therapy","type":"EXPERIMENTAL"},{"description":"Participants enrolled in this cohort will receive BBO-8520 once a day (QD) as monotherapy","label":"Cohort 2a - Dose Expansion Monotherapy","type":"EXPERIMENTAL"},{"description":"Participants enrolled in this cohort will receive BBO-8520 once a day (QD) in combination with pembrolizumab infusion (IV)","label":"Cohort 2b - Dose Expansion Combination Therapy","type":"EXPERIMENTAL"},{"description":"Participants enrolled in this cohort will receive BBO-8520 once a day (QD) in combination with BBO-10203 once a day (QD)","label":"Cohort 1b Safety Lead-In - Dose Expansion Doublet Combination Therapy","type":"EXPERIMENTAL"},{"description":"Participants enrolled in this cohort will receive BBO-8520 once a day (QD) in combination with BBO-10203 once a day (QD)","label":"Cohort 1b - Dose Expansion Doublet Combination Therapy","type":"EXPERIMENTAL"},{"description":"Participants enrolled in this cohort will receive BBO-8520 once a day (QD) in combination with BBO-10203 once a day (QD) and pembrolizumab infusion (IV)","label":"Cohort 1b Safety Lead-In - Dose Expansion Triplet Combination Therapy","type":"EXPERIMENTAL"},{"description":"Participants enrolled in this cohort will receive BBO-8520 once a day (QD) in combination with BBO-10203 once a day (QD) and pembrolizumab infusion (IV)","label":"Cohort 1b - Dose Expansion Triplet Combination Therapy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2031-09","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer","Metastatic Non-Small Cell Lung Cancer","NSCLC","KRAS G12C","Metastatic Lung Cancer","Advanced Lung Carcinoma"],"enrollment":{"count":350,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"BBO-8520","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"},{"name":"BBO-10203","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-03","lead_sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","official_title":"A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2031-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Adverse Events","timeFrame":"approximately 3 years"},{"measure":"Dose-limiting toxicities (DLTs)","timeFrame":"approximately 3 years"}],"references":[],"start_date":{"date":"2024-05-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT06343402"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/onkoras-101-nct06343402"}